BEXLUTRY: THE FDA-APPROVED LUTETIUM Lu 177 DOTATATE FOR ADULTS WITH SSTR+ GEP-NETs

BEXLUTRY IS A RADIOLIGAND THERAPY (RLT) WITH CHEMICAL, BIOLOGICAL, AND TARGETING CHARACTERISTICS COMPARABLE TO THE REFERENCE RLT1-3

BEXLUTRY was approved through the FDA’s 505(b)(2) approval pathway.4

BEXLUTRY1

Reference RLT2

SAME

Active ingredient:

Lutetium Lu 177 dotatate

SAME

Mechanism of action:

Delivers precise, targeted radiation to GEP-NET cells

SAME

Efficacy & safety:

Supported by the clinical trials of the reference RLT

SAME

Dosing strength and schedule:

7.4 GBq (200 mCi), every 8 weeks (±1 week) for a total of 4 doses

SAME

Route of administration:

Intravenous infusion

Single-dose vial of BEXLUTRY™ (lutetium Lu 177 dotatate).

BEXLUTRY contains different inactive ingredients compared to the reference RLT.1,2

SAME GUIDELINE RECOMMENDATION:

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) include lutetium Lu 177 dotatate as a recommended therapy for adult patients with well-differentiated GEP-NETs for first-line therapy or after progression on somatostatin analogs (SSAs).5

Under the 505(b)(2) approval pathway, the FDA determined that there was sufficient scientific basis for BEXLUTRY to rely on Lutathera’s clinical safety and efficacy findings. Accordingly, the label for BEXLUTRY contains identical clinical safety and efficacy data as the Lutathera label.1,2

Abbreviations

FDA, US Food and Drug Administration; GEP-NET, gastroenteropancreatic neuroendocrine tumor; NCCN, National Comprehensive Cancer Network® (NCCN®); SSTR+, somatostatin receptor–positive.

EXPANDING RADIOLIGAND THERAPY OPTIONS

Not all radioligand therapies are developed the same way.

BEXLUTRY was approved through the FDA's 505(b)(2) pathway,4 reflecting a differentiated regulatory approach within an evolving RLT landscape.

Read how experts are advancing the discussion around terminology, regulatory pathways, and the future of radiopharmaceutical options.

How BEXLUTRY works

BEXLUTRY has the same mechanism of action as the reference RLT.1,2

References

  1. BEXLUTRY. Prescribing information. Curium US LLC; 2026.
  2. Lutathera. Prescribing information. Advanced Accelerator Applications USA Inc; 2024.
  3. Data on file. Curium US LLC.
  4. Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs. News release. Curium. September 14, 2026. Accessed November 18, 2026. https://www.curiumpharma.com/fda-approval-bexlutry/
  5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Neuroendocrine and Adrenal Tumors V.1.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed April 28, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.